Volume : 13, Issue : 08, August – 2026

Title:

SOMATROGON: A LONG-ACTING GROWTH HORMONE ANALOG FOR PEDIATRIC GROWTH HORMONE DEFICIENCY – A COMPREHENSIVE REVIEW

Authors :

Heeba Fatima*, Asma Anjum, Ayesha Batool, Fouzia Khan

Abstract :

Growth hormone deficiency (GHD) is a clinically significant endocrine disorder characterized by impaired linear growth, delayed skeletal maturation, and metabolic abnormalities in pediatric populations. Recombinant human growth hormone (rhGH) therapy has been the cornerstone of management for several decades; however, the requirement for daily injections often leads to poor adherence and suboptimal clinical outcomes. Somatrogon is a novel long-acting recombinant growth hormone analog designed to reduce dosing frequency to once weekly while maintaining therapeutic efficacy. This review provides a detailed analysis of somatrogon, including its pharmacological profile, mechanism of action, pharmacokinetics, clinical efficacy, safety, and therapeutic advantages. Evidence suggests that somatrogon demonstrates non-inferiority to daily somatropin in improving height velocity, with comparable safety outcomes and improved patient compliance. The structural modification involving the addition of a C-terminal peptide prolongs its half-life and sustains insulin-like growth factor-1 (IGF-1) activity. Although currently approved for pediatric GHD, ongoing studies are evaluating its use in adult populations. Somatrogon represents a significant advancement in endocrine therapy, offering improved convenience and adherence without compromising efficacy.
Keywords: Somatrogon, Growth hormone deficiency, Long-acting GH, IGF-1, Pediatric endocrinology

Cite This Article:

Please cite this article in press Heeba Fatima et al., Somatrogon: A Long-Acting Growth Hormone Analog For Pediatric Growth Hormone Deficiency – A Comprehensive Review. Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. FDA. Ngenla (somatrogon-ghla) approval. 2023.
2. NCBI. Growth Hormone Deficiency. StatPearls; 2021.
3. Zelinska N, et al. Lancet Diabetes Endocrinol. 2017;5(9):727–736.
4. Deal CL, Saenger P. Endocr Dev. 2020;38:51–62.
5. EMA. Ngenla EPAR. 2022.
6. ClinicalTrials.gov. NCT03831880.
7. Pfäffle R, et al. Best Pract Res Clin Endocrinol Metab. 2021.
8. Lin Y, et al. Horm Res Paediatr. 2023.
9. Rosenfeld RG, et al. J Clin Endocrinol Metab. 2012.
10. Stanley T. Lancet Diabetes Endocrinol. 2016.
11. Wit JM, et al. Horm Res Paediatr. 2019.
12. Yuen KCJ, et al. Endocr Rev. 2019.
13. Bright GM. J Pediatr Endocrinol Metab. 2019.
14. Cohen P, et al. Growth Horm IGF Res. 2007.
15. Ranke MB. Endocr Dev. 2010.
16. Sävendahl L, et al. Horm Res Paediatr. 2020.
17. Grimberg A, et al. Horm Res Paediatr. 2016.
18. Cook DM, et al. J Clin Endocrinol Metab. 2009.
19. Ho KK. J Clin Endocrinol Metab. 2007.
20. Baxter RC. Endocr Rev. 2014.
21. Deodati A, Cianfarani S. Eur J Endocrinol. 2017.
22. Kargi AY, Merriam GR. Endocrinol Metab Clin North Am. 2013.
23. Christiansen JS, et al. Endocr Rev. 2021.
24. Johannsson G, et al. Clin Endocrinol. 2020.
25. Sävendahl L, et al. J Clin Endocrinol Metab. 2020

Volume : 13, Issue : 08, August – 2026

Title:

EVALUATION OF ANTIHYPERLIPIDEMIC ACTIVITY OF SAPINDUS EMARGINATUS IN RATS

Authors :

Chinthala Jamima*, Dr.R.narasimha Rao, Dr.N. Raghunandhan

Abstract :

Obesity and hyperlipidemia have become major disorders predominantly causing prevailing cardiovascular diseases and ultimately death. The prolonged use of anti-obesity drugs and statins for reducing obesity and blood lipid levels is leading toward adverse effects of kidneys and muscles, specifically rhabdomyolysis. The objective of this study is to evaluate potential of seeds of Sapindus emarginatus against hyperlipidemia. In this model of Hyperlipidemia, 30 adult male wistar rats (200-250gms) were evenly divided into 5 groups in both groups. Group-1 and Group-2 served as untreated and model controls respectively, while Group-3, 4 and 5 were the treatments groups which were simultaneously treated with standard, 100 and 200 mg/kg extract respectively along with High Fat Diet. On last day, blood samples for biochemical parameters, were obtained under inhaled diether anaesthesia. The outcomes of this study were expressed as mean standard error and data were evaluated by using analysis of variance followed by multiple comparisons. Oral administration of 100 mg/ kg and 200mg/kg body weight of Methanolic extract residual fraction of Moringa oleifera. Leaves exhibited a significant reduction (P < 0.01) in serum lipid parameters such as triglycerides, total cholesterol, low density lipoprotein (LDL), very LDL and increase in high density lipoprotein in hyperlipidemic rats when compared with hyperlipidemic control in both models. Our results demonstrated that Methanolic extract fraction of Sesbania grandiflora. Possessed significant antihyperlipidemic activity.
Keywords: Sesbania grandiflora, Cholesterol, LDL, triglycerides and antihyperlipidemic activity.

Cite This Article:

Please cite this article in press Chinthala Jamimaet al., Evaluation of Antihyperlipidemic activity of Sapindus Emarginatus in rats,, Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. Amit G, Vandana S, Sidharth M. HYPERLIPIDEMIA: An Updated Review. Inter J of Biopharma & Toxicol Res 2011;1:81-89.
2. Virchow RP, Thrombose IG. In Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt-am-Main, Meidinger Sohn & Company 1856, S 458-564.
3. Ankur rohilla, Nidhi Dagar, Seema Rohilla, Amarjeet Dahiya, Ashok Kushnoor. HYPERLIPIDEMIA- a deadly pathological condition. Inter J Curr Pharma Res 2012;4:15-18
4. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369-77.
5. Grundy SM, Vega GL. Hypertriglyceridemia: causes and relation to coronary heart disease – Semin. Thromb. Hemost 1988;14:249-64.
6. Dargel R. Lipoproteins and the etiopathogenesis of atherosclerosis. Zentralbl Allg Pathol 1989; 135: 501-504.